World Psychiatry最新文献

{"title":"Meeting the UN Sustainable Development Goals for mental health: why greater prioritization and adequately tracking progress are critical.","authors":"Jody Heymann, Aleta Sprague","doi":"10.1002/wps.21090","DOIUrl":"https://doi.org/10.1002/wps.21090","url":null,"abstract":"","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 2","pages":"325-326"},"PeriodicalIF":73.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168142/pdf/WPS-22-325.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9442880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WPA Scientific Sections 2020-2023: from strengthened backbone to motor of innovation.","authors":"Thomas G Schulze","doi":"10.1002/wps.21105","DOIUrl":"https://doi.org/10.1002/wps.21105","url":null,"abstract":"","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 2","pages":"345"},"PeriodicalIF":73.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168144/pdf/WPS-22-345.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9442892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promising approaches in the search for biomarkers of bipolar disorder.","authors":"Mary L Phillips","doi":"10.1002/wps.21080","DOIUrl":"https://doi.org/10.1002/wps.21080","url":null,"abstract":"World Psychiatry 22:2 June 2023 er discovery. As well, standard data collection protocols should be developed for deep clinical phenotyping, cognitive assessments, biological sampling, and electrophysiological and imaging procedures, to enable pooling of data from centers around the world. The AD Neuroimaging Initiative (ADNI) is an exemplar of such effort. ADNI began in 2004 with substantial publicprivate partnership funding that allowed academ ic centers internationally to standardize data collection and pool data, which led to discovery of biomarkers for AD. Similar initiatives in psychiatry, such as the Establish ing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMBARC) project, the Canadian Biomarker Integration Network in Depression (CANBIND), the Personalized Prognostic Tools for Early Psychosis Management (PRONIA) Consortium, and the planned longitudinal cohort study by the recently launched BD Integrated Network, are clearly steps in the right direction. Moreover, industrysponsored phase 2/3 clinical trial programs that ascertain the efficacy of new drugs for psychiatric disorders generate vast amounts of treatment data. These data could be a huge resource for biomarker discovery if the trials implement standardized data collection protocols that include deep clinical phenotyping and biological sampling, and the data are made available for pooling with other networks. Looking to the future, the probability of dis covering diagnostic biomarkers that map precisely to specific DSM5 disorders is very low, given the heterogeneity of the dis orders and the symptom overlap among them. However, the emerging evidence re viewed by AbiDargham et al and the continuing advances in research methods for biomarker discovery offer a ray of hope that susceptibility markers for disease conversion and predictive biomarkers for treatment response will become a future reality in psychiatry.","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 2","pages":"264-265"},"PeriodicalIF":73.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168172/pdf/WPS-22-264.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9436367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The WPA Action Plan 2020-2023: an updated report.","authors":"Afzal Javed","doi":"10.1002/wps.21101","DOIUrl":"10.1002/wps.21101","url":null,"abstract":"","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 2","pages":"341-342"},"PeriodicalIF":73.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168146/pdf/WPS-22-341.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9442882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronotype and mental health: timing seems to matter, but how, why, and for whom?","authors":"Brant P Hasler","doi":"10.1002/wps.21092","DOIUrl":"https://doi.org/10.1002/wps.21092","url":null,"abstract":"329 These lessons and this innovative approach to trauma intervention, we believe, is a pathway to a more humane and effective way to help a variety of trauma populations. The posttraumatic growth process is very similar no matter the originating traumas. What is necessary is for expert companions to be an essential part of the response to trauma survivors and to appreciate the opportunities for much more than a recovery. Trauma changes people, but the changes do not need to be diminishment. They are more likely to be growth.","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 2","pages":"329-330"},"PeriodicalIF":73.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168154/pdf/WPS-22-329.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10299629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Candidate biomarkers in psychiatric disorders: state of the field.","authors":"Anissa Abi-Dargham, Scott J Moeller, Farzana Ali, Christine DeLorenzo, Katharina Domschke, Guillermo Horga, Amandeep Jutla, Roman Kotov, Martin P Paulus, Jose M Rubio, Gerard Sanacora, Jeremy Veenstra-VanderWeele, John H Krystal","doi":"10.1002/wps.21078","DOIUrl":"10.1002/wps.21078","url":null,"abstract":"<p><p>The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can aid in objectively diagnosing patients and providing individualized treatment recommendations. Here we review and critically evaluate the evidence for the most promising biomarkers in the psychiatric neuroscience literature for autism spectrum disorder, schizophrenia, anxiety disorders and post-traumatic stress disorder, major depression and bipolar disorder, and substance use disorders. Candidate biomarkers reviewed include various neuroimaging, genetic, molecular and peripheral assays, for the purposes of determining susceptibility or presence of illness, and predicting treatment response or safety. This review highlights a critical gap in the biomarker validation process. An enormous societal investment over the past 50 years has identified numerous candidate biomarkers. However, to date, the overwhelming majority of these measures have not been proven sufficiently reliable, valid and useful to be adopted clinically. It is time to consider whether strategic investments might break this impasse, focusing on a limited number of promising candidates to advance through a process of definitive testing for a specific indication. Some promising candidates for definitive testing include the N170 signal, an event-related brain potential measured using electroencephalography, for subgroup identification within autism spectrum disorder; striatal resting-state functional magnetic resonance imaging (fMRI) measures, such as the striatal connectivity index (SCI) and the functional striatal abnormalities (FSA) index, for prediction of treatment response in schizophrenia; error-related negativity (ERN), an electrophysiological index, for prediction of first onset of generalized anxiety disorder, and resting-state and structural brain connectomic measures for prediction of treatment response in social anxiety disorder. Alternate forms of classification may be useful for conceptualizing and testing potential biomarkers. Collaborative efforts allowing the inclusion of biosystems beyond genetics and neuroimaging are needed, and online remote acquisition of selected measures in a naturalistic setting using mobile health tools may significantly advance the field. Setting specific benchmarks for well-defined target application, along with development of appropriate funding and partnership mechanisms, would also be crucial. Finally, it should never be forgotten that, for a biomarker to be actionable, it will need to be clinically predictive at the individual level and viable in clinical settings.</p>","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 2","pages":"236-262"},"PeriodicalIF":73.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168176/pdf/WPS-22-236.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9452393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention.","authors":"Nora D Volkow,&nbsp;Carlos Blanco","doi":"10.1002/wps.21073","DOIUrl":"https://doi.org/10.1002/wps.21073","url":null,"abstract":"<p><p>Substance use disorders (SUDs) are highly prevalent and exact a large toll on individuals' health, well-being, and social functioning. Long-lasting changes in brain networks involved in reward, executive function, stress reactivity, mood, and self-awareness underlie the intense drive to consume substances and the inability to control this urge in a person who suffers from addiction (moderate or severe SUD). Biological (including genetics and developmental life stages) and social (including adverse childhood experiences) determinants of health are recognized factors that contribute to vulnerability for or resilience against developing a SUD. Consequently, prevention strategies that target social risk factors can improve outcomes and, when deployed in childhood and adolescence, can decrease the risk for these disorders. SUDs are treatable, and evidence of clinically significant benefit exists for medications (in opioid, nicotine and alcohol use disorders), behavioral therapies (in all SUDs), and neuromodulation (in nicotine use disorder). Treatment of SUDs should be considered within the context of a Chronic Care Model, with the intensity of intervention adjusted to the severity of the disorder and with the concomitant treatment of comorbid psychiatric and physical conditions. Involvement of health care providers in detection and management of SUDs, including referral of severe cases to specialized care, offers sustainable models of care that can be further expanded with the use of telehealth. Despite advances in our understanding and management of SUDs, individuals with these conditions continue to be stigmatized and, in some countries, incarcerated, highlighting the need to dismantle policies that perpetuate their criminalization and instead develop policies to ensure support and access to prevention and treatment.</p>","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 2","pages":"203-229"},"PeriodicalIF":73.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168177/pdf/WPS-22-203.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9436379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The time is now to start evaluating biomarkers in the clinic.","authors":"Aristotle Voineskos","doi":"10.1002/wps.21082","DOIUrl":"https://doi.org/10.1002/wps.21082","url":null,"abstract":"267 methods. Applying a reverse engineering approach, working backwards from treatment outcome heterogeneity to identify treatmentselection biomarkers (which may not have any direct causal role in the pathophysiology of disease), has already proven to be valid and potentially productive . The clinical utility of such biomarkers rests on their potential to allow practitioners to move beyond the current trialanderror standard, thus shortening time to remission and minimizing exposure to potential adverse effects. Application of treatmentselection biomarkers would further transcend the concept of “clinical stages” of treatment resistance, enabling patients to proceed immediately to more intensive treatments that, under current care models, are withheld until the patient demonstrates nonresponse to standard treatments. Researchers should remain mindful of the seductive nature of the classical forward","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 2","pages":"267-268"},"PeriodicalIF":73.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168165/pdf/WPS-22-267.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9436373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WPA scientific meetings 2020-2023.","authors":"Edmond H Pi","doi":"10.1002/wps.21106","DOIUrl":"https://doi.org/10.1002/wps.21106","url":null,"abstract":"","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 2","pages":"345-346"},"PeriodicalIF":73.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168158/pdf/WPS-22-345.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9442888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers for clinical use in psychiatry: where are we and will we ever get there?","authors":"Lakshmi N Yatham","doi":"10.1002/wps.21079","DOIUrl":"10.1002/wps.21079","url":null,"abstract":"","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 2","pages":"263-264"},"PeriodicalIF":73.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168147/pdf/WPS-22-263.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9436368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}